|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1- positive, antiretroviral-naive subjects 显示文摘 | MOYLE G BOFFITO M STOEHR A | 2010 | Antimicrobial Agents and Chemotherapy2010，54，8： | 1 |
| 2 | A New Ti-Based Non-Evaporable getter显示文摘 | Giorgi E Boffito C Boiognesi M | 1990 | Vacuum1990，41，79： | 1 |
| 3 | Atazanavir enhances saquinavir hard-gel concentrations in a ritonavirboosted once-daily regimen 显示文摘 | Boffito M Kurowski M Kruse G | 2004 | AIDS2004，18，： | 1 |
| 4 | Effects of different meal compositions and fasted state on the oral bioavailability of etravirine 显示文摘 | Scholler-Gyure M Boffito M Pozniak AL | 2008 | Pharmacotherapy2008，28，10： | 1 |
| 5 | The management of HIV- 1 protease inhibitor pharmacokinetic interactions显示文摘 | Winston A Boffito M | 2005 | J Antimicrob Chemother2005，56，1： | 1 |
| 6 | A new Ti-based non-evaporable getter显示文摘 | Giorgi E Boffito C Boiognesi M | 1990 | Vacuum1990，41，79： | 1 |
| 7 | Safety,immunogenicity and efficacy assessment of HIV immunotherapy in a multi centre, double-blind, randomised, Placebo-controlled Phase Ib human trial显示文摘 | Boffito M Fox J Bowman C | 2013 | Vaccine2013，31，48： | 1 |
| 8 | Phase 2a randomized controlled trial of short-term activity,safety,and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor,RDEA806,in HIV-l-positive,antiretroviral-nave subjects 显示文摘 | Moyle G Boffito M Stoehr A | 2010 | Antimicrob Agents Chemther2010，54，8： | 1 |
| 9 | A new Ti - based non - evaporable getter 显示文摘 | Giorgi E Boffito C Bolognesi M | 1990 | Vacuum1990，，41： | 1 |
| 10 | Protein binding in antiretro- viral therapies 显示文摘 | Boffito M Black D J Blaschke TF | 2003 | AIDS Res Hum Retrovir2003，19，： | 1 |
| 11 | Lopinavir protein binding in vivo through 12 - hour dosing interval 显示文摘 | Boffito M Hoggard PG Lindup WE | 2004 | Ther Drug Monit2004，26，： | 1 |
| 12 | Investigation oflow-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays显示文摘 | Yilmaz S Boffito M Collot-Teixeira S | 2010 | Genomics2010，96，1： | 1 |
| 13 | Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects显示文摘 | Moyle G Boffito M Stoehr A | 2010 | Antimicrob Agents Chemther2010，54，8： | 1 |
| 14 | The management of HIV - 1 protease inhibitor pharmacokinetic interactions 显示文摘 | Winston A Boffito M | 2005 | J Antimicrob Chemother2005，56，1： | 1 |
| 15 | Prevention of atheroselerosis in patients living with HIV显示文摘 | De Lorenzo F Boffito M Collot-Teixeira S | 2009 | Vase Health Risk Manag2009，5，1： | 1 |
| 16 | Pharmacokinetics and pharmaco-dynamics of drug interactions involving rifampicin,rifabutin andantimalarial drugs 显示文摘 | Sousa M Pozniak A Boffito M | 2008 | J Antimicrob Chemother2008，62，5： | 1 |
| 17 | The pharmacokinetics of HIV protease inhibitor combinations显示文摘 | Boffito M Maitland D Samarasinghe Y | 2005 | Curr Opin Infect Dis2005，18，1： | 1 |
| 18 | Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells显示文摘 | Mattu C Pabari RM Boffito M | 2013 | Eur J Pharm Biopharm2013，85，3： | 1 |
| 19 | Effect of amodified saquinavir/ritonavir dosing regimen with lower doselead-in phase on QTc interval,pharmacokinetics,antiviralactivity and safety in treatment-na ve HIV-1-infected patients显示文摘 | BOFFITO M JACKSON A POZNIAK A | 2015 | Drugs in R & D2015，15，1： | 1 |
| 20 | Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults 显示文摘 | LAMORDE M BYAKIKA-KIBWIKA P BOFFITO M | 2012 | J Acquir Immune Defic Syndr2012，60，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员